In the phase 3 SUBITO trial, researchers aimed to compare outcomes with intensified alkylating chemotherapy to those with an HRD-targeting regimen.
Adding venetoclax to hypomethylating agents increased composite remission but did not improve overall survival in HR-MDS.
Each additional hour per day of prolonged sedentary behavior is associated with a higher hazard of cancer death ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results